095700 — Genexine Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for Genexine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS/A	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	18,543	36,828	16,139	4,427	2,933
Cost of Revenue
Gross Profit	11,677	31,806	11,363	387	-1,241
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	6,002	57,023	50,604	46,823	39,876
Operating Profit	12,541	-20,195	-34,465	-42,397	-36,943
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	27,536	-48,876	-56,831	-66,860	-65,412
Provision for Income Taxes
Net Income After Taxes	27,536	-48,876	-56,831	-66,860	-63,706
Minority Interest
Net Income Before Extraordinary Items
Net Income	27,570	-48,042	-55,974	-66,874	-63,706
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	21,304	-48,042	-55,974	-66,874	-63,706
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-894	-1,360	-2,665	-1,624	-1,513
Dividends per Share